We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Open Label Study to Evaluate Safety and Efficacy of 2 Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: March 29, 2012
Last Update Posted: April 10, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Ambit Biosciences Corporation
Information provided by (Responsible Party):
Daiichi Sankyo, Inc.
This study will evaluate two doses of Quizartinib in patients with relapsed or refractory acute myeloid leukemia who are also FMS-like tyrosine kinase - internal tandem duplication ( FLT3-ITD) positive. Patient will be randomly assigned in a 1:1 ratio to one of two treatment arms. Both treatment arms will receive Quizartinib but at different doses. The study treatment is taken orally in 28 day cycles until either disease progression occurs or an unacceptable toxicity occurs. In addition to the study assessments to evaluate the disease, blood will be drawn to measure drug levels and biomarkers. Patients will be followed for survival at three month intervals after the end of treatment.

Condition Intervention Phase
Leukemia, Myeloid, Acute Drug: AC220 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2, Randomized, Open-Label Study of the Safety and Efficacy of Two Doses of Quizartinib (AC220; ASP2689) in Subjects With FLT3-ITD Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

Resource links provided by NLM:

Further study details as provided by Daiichi Sankyo, Inc.:

Primary Outcome Measures:
  • Composite Complete Response (CRc) [ Time Frame: Evaluated after two complete 28 day cycles ]
    CRc is defined as Complete remission (CR) + Complete remission with incomplete platelet recovery (CRp) + Complete remission with incomplete hematological recovery (CRi)

  • Grade 2 or higher QT interval corrected for heart rate using Fridericia's factor (QTcF) prolongation at each dose level AC220 [ Time Frame: Evaluated after two complete 28 day cycles ]

Secondary Outcome Measures:
  • Complete Remission (CR) [ Time Frame: Evaluated after two complete 28 day cycles ]
    Subject must have bone marrow regenerating normal hematopoietic cells and achieve a morphologic leukemia-free state (< 5% bone marrow blasts in bone marrow, no blasts with Auer rods and no persistence of extramedullary disease) and must have an absolute neutrophil count (ANC) ≥ 1x109/L and platelet count ≥ 100 x 109/L and they will be red blood cell (RBC) and platelet transfusion independent (defined as 4 weeks without RBC transfusions and 1 week without platelet transfusion).

  • Overall Survival (OS) [ Time Frame: Evaluated at end of study, up to 6 months ]
    Time from randomization until death

  • Event free survival (EFS) [ Time Frame: Evaluated at end of study, up to 6 months ]
    Time from randomization until documented relapse or death

  • Leukemia free survival (LFS) [ Time Frame: Evaluated at end of study, up to 6 months ]
    Time from first CRc until documented relapse or death

  • Duration of remission [ Time Frame: Evaluated at end of study, up to 6 months ]
    Time from first documented remission until documented relapse

  • Safety assessed by recording adverse events, laboratory assessments, vital signs, electrocardiograms (ECGs), and Eastern Cooperative Oncology Group (ECOG) performance scores [ Time Frame: Continuous, up to 6 months from study end ]
  • Time to treatment response (TTR) [ Time Frame: Evaluated at end of study, up to 6 months ]
    Time from randomization until the first measured response

  • Percentage of subjects undergoing hematopoietic stem cell transplantation (HSCT) [ Time Frame: Evaluated at end of study, up to 6 months ]

Enrollment: 76
Study Start Date: April 2012
Study Completion Date: March 2015
Primary Completion Date: March 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: AC220 Dose Level 1 Drug: AC220
Other Names:
  • Quizartinib
  • ASP2689
Experimental: AC220 Dose Level 2 Drug: AC220
Other Names:
  • Quizartinib
  • ASP2689


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subject has morphologically documented primary AML or AML secondary to myelodysplastic syndrome (MDS) as defined by the World Health Organization (WHO) criteria, as determined by pathology review at the treating institution and has relapsed or is refractory after 1 second line (salvage) regimen or after HSCT
  • Subject is positive for FLT3-ITD activating mutation in bone marrow or peripheral blood (>10% allelic ratio)
  • ECOG performance status of 0 to 2
  • In the absence of rapidly progressing disease clearly documented by the investigator, the interval from prior treatment to time of AC220 administration will be at least 2 weeks (14 days) for prior cytotoxic agents or at least 5 half-lives for prior noncytotoxic agents, including immunosuppressive therapy post HSCT
  • Persistent chronic clinically significant nonhematological toxicities from prior treatment (including chemotherapy, kinase inhibitors, immunotherapy, experimental agents, radiation, HSCT, or surgery) must be Grade ≤ 1
  • Patients - both males and females - with reproductive potential are eligible

Exclusion Criteria:

  • Subject received previous treatment with AC220
  • Subject has a diagnosis of acute promyelocytic leukemia
  • Subject has a diagnosis of chronic myelogenous leukemia (CML) in blast crisis
  • Subject has AML or antecedent MDS secondary to prior chemotherapy
  • Subject has had HSCT and has either of the following:
  • Donor lymphocyte infusion (DLI) is not permitted during the study or < 30 days prior to study entry
  • Subject has clinically active CNS leukemia. A subject is considered eligible if CNS leukemia is controlled and subject is receiving intrathecal (IT) therapy at study entry. Subjects should continue to receive IT therapy (or cranial radiation) as clinically indicated
  • Subject has received concurrent chemotherapy, immunotherapy, or radiotherapy within 14 days prior to the first dose of AC220, or any ancillary therapy that is considered to be investigational (i.e., used for non-approved indications(s) and in the context of a research investigation) within 30 days or 5 half-lives (whichever is longer) prior to the first dose of study drug
  • Subject requires treatment with concomitant drugs that prolong QT/QTc interval or with strong inhibitors or inducers of cytochrome P450- isozyme3A4 (CYP3A4) with the exception of antibiotics, antifungals, and antivirals that are used as standard of care post-transplant or to prevent or treat infections and other such drugs that are considered absolutely essential for the care of the subject
  • Subject requires treatment with anticoagulant therapy
  • Subject has a known positive test for human immunodeficiency virus, hepatitis C, or hepatitis B surface antigen
  • Subject had major surgery within 4 weeks prior to first dose of AC220
  • Subject has uncontrolled or significant cardiovascular disease, including
  • Subject has a pre-existing disorder predisposing the subject to a serious or life-threatening infection (e.g. cystic fibrosis, congenital or acquired immunodeficiency, bleeding disorder, or cytopenias not related to AML)
  • Subject has an active uncontrolled acute or chronic systemic fungal, bacterial, viral, or other infection
  • Subject has any of the following laboratory values:
  • Subject is a female with a positive pregnancy test, pregnant, or breastfeeding
  • Subject has any medical, psychiatric, addictive or other kind of disorder which compromises the ability of the subject to give written informed consent and/or to comply with procedures
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01565668

  Hide Study Locations
United States, California
UCLA School of Medicine
Los Angeles, California, United States, 90095
United States, Illinois
Northwestern University
Chicago, Illinois, United States, 60611
University of Chicago
Chicago, Illinois, United States, 60637
United States, Maryland
University of Maryland Greenebaum Cancer Center
Baltimore, Maryland, United States, 21201
John Hopkins University
Baltimore, Maryland, United States, 21231
United States, Massachusetts
Tufts University School of Medicine-Tufts Medical Center
Boston, Massachusetts, United States, 02111
United States, Minnesota
University of Minnesota
Minneapolis, Minnesota, United States, 55455
Mayo Clinic
Rochester, Minnesota, United States, 55905
United States, New Jersey
Hackensack University Medical Center
Hackensack, New Jersey, United States, 07601
United States, New York
Memorial Sloan-Kettering Cancer Center
New York, New York, United States, 10021
Weill Cornell Medical College
New York, New York, United States, 10065
United States, Pennsylvania
Penn State Milton S. Hershey Medical Center
Hershey, Pennsylvania, United States, 17033
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
United States, South Carolina
Medical University of South Carolina, Hollings Cancer Center
Charleston, South Carolina, United States, 29403
United States, Tennessee
Vanderbilt University, Vanderbilt Ingram Cancer Center
Nashville, Tennessee, United States, 37232
United States, Texas
UT Southwestern Medical Center, Simmons Cancer Center
Dallas, Texas, United States, 75390
MD Anderson
Houston, Texas, United States, 77030
United States, Washington
Fred Hutchinson Cancer Research Center
Seattle, Washington, United States, 98109
CHU d'Angers
Angers, France, 49033
CHU de Grenoble
Grenoble, France, 38043
Hôpital Saint Antoine
Paris, France, 75571
Hôpital Haut Lévêque
Pessac, France, 33600
Universitaria Policlinico S. Orsola Malpighi, Institute of Hemtology "L. & A. Seragnoli"
Bologna, Italy, 40138
United Kingdom
Nottingham University Hospitals
Nottingham, England, United Kingdom
Sponsors and Collaborators
Daiichi Sankyo, Inc.
Ambit Biosciences Corporation
Study Director: Guy Gammon, MB, BS, MRCP Medical Monitor, Ambit Biosciences Corporation
  More Information

Responsible Party: Daiichi Sankyo, Inc.
ClinicalTrials.gov Identifier: NCT01565668     History of Changes
Other Study ID Numbers: 2689-CL-2004
2011-005408-13 ( EudraCT Number )
First Submitted: March 27, 2012
First Posted: March 29, 2012
Last Update Posted: April 10, 2017
Last Verified: April 2017

Keywords provided by Daiichi Sankyo, Inc.:
FLT3-ITD positive Acute Myeloid Leukemia (AML)

Additional relevant MeSH terms:
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Neoplasms by Histologic Type